-+ 0.00%
-+ 0.00%
-+ 0.00%

Canaccord Genuity Maintains Buy on Intellia Therapeutics, Lowers Price Target to $49

Benzinga·05/12/2026 21:23:43
Listen to the news
Canaccord Genuity analyst Whitney Ijem maintains Intellia Therapeutics (NASDAQ:NTLA) with a Buy and lowers the price target from $58 to $49.